Gujarat Themis Biosyn Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 382.7 as of 05 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 yearsThe P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 yearsThe Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 174.33 crore on March 2021 to ₹ 144 crore on March 2025 . This represents a CAGR of -3.75% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The revenue of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 7.28 crore as compare to the Sep '25 revenue of ₹ 4.17 crore. This represent the growth of 74.58% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0.3 crore as compare to the Sep '25 ebitda of ₹ -2.79 crore. This represent the decline of -110% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ -5.17 crore to ₹ -3.13 crore over 7 quarters. This represents a CAGR of -24.93% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991.
The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003.
Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. The Company develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Krebs Biochemicals & Industries Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Krebs Biochemicals & Industries Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,170 Cr while Market cap of Krebs Biochemicals & Industries Ltd is 131 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Krebs Biochemicals & Industries Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Krebs Biochemicals & Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Krebs Biochemicals & Industries Ltd?

As of May 5, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹382.7. On the other hand, Krebs Biochemicals & Industries Ltd stock price is INR ₹60.79.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Krebs Biochemicals & Industries Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Krebs Biochemicals & Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.